CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor

Oncogene

Volumn 35, Issue 40, 2016, Pages 5317-5327

  Nodomi, S ^a   Umeda, K ^a   Saida, S ^a   Kinehara, T ^a   Hamabata, T ^a   Daifu, T ^a   Kato, I ^a   Hiramatsu, H ^a   Watanabe, K I ^a   Kuwahara, Y ^b   Iehara, T ^b   Adachi, S ^a   Konishi, E ^b   Nakahata, T ^c   Hosoi, H ^b   Heike, T ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD146 ANTIBODY; CD146 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN KINASE B; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; MCAM PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL SELF-RENEWAL; CHILDHOOD CANCER; DRUG TARGETING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHABDOID TUMOR; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT; ADOLESCENT; ADULT; AGED; ANIMAL; BIOSYNTHESIS; CELL LINEAGE; CHILD; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; MIDDLE AGED; NEURAL CREST; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIGENS, CD146; APOPTOSIS; BIOMARKERS, TUMOR; CARCINOGENESIS; CELL LINEAGE; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MIDDLE AGED; NEURAL CREST; RHABDOID TUMOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962045969     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.72     Document Type: Article

References (52)

1. Sultan I, Qaddoumi I, Rodriguez-Galindo C, Nassan AA, Ghandour K, Al-Hussaini M. Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors. Pediatr Blood Cancer 2010; 54: 35-40
2. Ginn KF, Gajjar A. Atypical teratoid rhabdoid tumor: current therapy, and future directions. Front Oncol 2012; 2: 114
3. Weeks DA, Beckwith JB, Mierau GW, Luckey DW. Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms' Tumor Study Pathology Center. Am J Surg Pathol 1989; 13: 439-458
4. Ho DM, Hsu CY, Wong TT, Ting LT, Chiang H. Atypical teratoid/rhabdoid tumor of the central nervous system: a comparative study with primitive neuroectodermal tumor/medulloblastoma. Acta Neuropathol 2000; 99: 482-488
5. Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004; 22: 2877-2884
6. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998; 394: 203-206
7. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line, and acquired mutations of INI1 in atypical teratoid, and rhabdoid tumors. Cancer Res 1999; 59: 74-79
8. Van Den Heuvel-Eibrink MM, van Tinteren H, Rehorst H, Coulombe A, Patte C, de Camargo B, et al. Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group. Pediatr Blood Cancer 2011; 56: 733-737
9. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-296
10. Visvader JE, Lindeman GJ. Cancer stem cells: current status, and evolving complexities. Cell Stem Cell 2012; 10: 717-728
11. Clevers H. The cancer stem cell: premises, promises, and challenges. Nat Med 2011; 17: 313-319
12. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988
14. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401
15. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges, and opportunities for anticancer drug discovery. Nat Rev Drug Disc 2009; 8: 806-823
16. Okuno K, Ohta S, Kato H, Taga T, Sugita K, Takeuchi Y. Expression of neural stem cell markers in malignant rhabdoid tumor cell lines. Oncol Rep 2010; 23: 485-492
17. Gadd S, Sredni ST, Huang CC, Perlman EJ. Rhabdoid tumor: gene expression clues to pathogenesis, and potential therapeutic targets. Lab Invest 2010; 90: 724-738
18. Parham DM, Weeks DA, Beckwith JB. The clinicopathologic spectrum of putative extrarenal rhabdoid tumors. An analysis of 42 cases studied with immunohistochemistry or electron microscopy. Am J Surg Pathol 1994; 18: 1010-1029
19. Chiou SH, Kao CL, Chen YW, Chien CS, Hung SC, Lo JF, et al. Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PloS One 2008; 3: e2090
20. Yanagisawa S, Kadouchi I, Yokomori K, Hirose M, Hakozaki M, Hojo H, et al. Identification, and metastatic potential of tumor-initiating cells in malignant rhabdoid tumor of the kidney. Clin Cancer Res 2009; 15: 3014-3022
21. Shih IM. The role of CD146 (Mel-CAM) in biology, and pathology. J Pathol 1999; 189: 4-11
22. Wang Z, Yan X. CD146, a multi-functional molecule beyond adhesion. Cancer Lett 2013; 330: 150-162
23. Pujades C, Guez-Guez B, Dunon D. Melanoma cell adhesion molecule (MCAM) expression in the myogenic lineage during early chick embryonic development. Int J Dev Biol 2002; 46: 263-266
24. Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth, and metastasis of human melanoma. Cancer Res 2002; 62: 5106-5114
25. Zhong Y, Guan K, Guo S, Zhou C, Wang D, Ma W, et al. Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells. Cancer Lett 2010; 299: 150-160
26. Chen D, Bhat-Nakshatri P, Goswami C, Badve S, Nakshatri H. ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells, and metastasis in breast cancer. Cancer Res 2013; 73: 5821-5833
27. Meacham CE, Morrison SJ. Tumour heterogeneity, and cancer cell plasticity. Nature 2013; 501: 328-337
28. Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T, et al. Reciprocal regulation of MelCAM, and AKT in human melanoma. Oncogene 2003; 22: 6891-6899
29. Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 2012; 120: 2330-2339
30. Tu T, Zhang C, Yan H, Luo Y, Kong R, Wen P, et al. CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis, and vascular development. Cell Res 2015; 25: 275-287
31. Laplante M, Sabatini DM. mTOR signaling in growth control, and disease. Cell 2012; 149: 274-293
32. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes, and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35
33. Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis, and tumor growth. Blood 2003; 102: 184-191
34. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells-perspectives on current status, and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-9344
35. Jiang X, Gwye Y, Russell D, Cao C, Douglas D, Hung L, et al. CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 2010; 10: 116
36. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. Phenotypic heterogeneity, and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci USA 2011; 108: 6468-6473
37. Jouve N, Despoix N, Espeli M, Gauthier L, Cypowyj S, Fallague K, et al. The involvement of CD146, and its novel ligand Galectin-1 in apoptotic regulation of endothelial cells. J Biol Chem 2013; 288: 2571-2579
38. McGary EC, Heimberger A, Mills L, Weber K, Thomas GW, Shtivelband M, et al. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res 2003; 9: 6560-6566
39. Zhang Y, Zheng C, Zhang J, Yang D, Feng J, Lu D, et al. Generation, and characterization of a panel of monoclonal antibodies against distinct epitopes of human CD146. Hybridoma 2008; 27: 345-352
40. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, et al. Secretion of angiogenic, and antiapoptotic factors by human adipose stromal cells. Circulation 2004; 109: 1292-1298
41. Yoshimura K, Shigeura T, Matsumoto D, Sato T, Takaki Y, Aiba-Kojima E, et al. Characterization of freshly isolated, and cultured cells derived from the fatty, and fluid portions of liposuction aspirates. J Cell Physiol 2006; 208: 64-76
42. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100: 3175-3182
43. Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2 R gamma(null) mice in vivo. J Immunol 2009; 183: 4782-4791
44. Shiokawa M, Takahashi T, Murakami A, Kita S, Ito M, Sugamura K, et al. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun 2010; 399: 733-737
45. Sawyers CL. The cancer biomarker problem. Nature 2008; 452: 548-552
46. Tomlinson GE, Breslow NE, Dome J, Guthrie KA, Norkool P, Li S, et al. Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol 2005; 23: 7641-7645
47. Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age, and older with radiation therapy, and high-dose alkylator-based chemotherapy. J Clin Oncol 2005; 23: 1491-1499
48. Sugimoto T, Hosoi H, Horii Y, Ishida H, Mine H, Takahashi K, et al. Malignant rhabdoid-tumor cell line showing neural, and smooth-muscle-cell phenotypes. Int J Cancer 1999; 82: 678-686
49. Kuroda H, Moritake H, Sawada K, Kuwahara Y, Imoto I, Inazawa J, et al. Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1, and p16. Cancer Genet Cytogenet 2005; 158: 172-179
50. Katsumi Y, Kuwahara Y, Tamura S, Kikuchi K, Otabe O, Tsuchiya K, et al. Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells, and interleukin-2 augments the cytotoxicity. Clin Cancer Res 2008; 14: 1192-1199
51. Misawa A, Hosoi H, Imoto I, Iehara T, Sugimoto T, Inazawa J. Translocation (1; 22) (p36; q11.2) with concurrent del(22)(q11.2) resulted in homozygous deletion of SNF5/INI1 in a newly established cell line derived from extrarenal rhabdoid tumor. J Human Genet 2004; 49: 586-589
52. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells, and self-renewal. Clin Cancer Res 2010; 16: 3113-3120